Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Cephalexin Suspensions in Healthy Volunteers
NCT02490670Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cefalexin in bacterial infection (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) and Maximum Concentration (Cmax). Started Jul 2015; status: completed.
02
Drugs
cefalexin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02490670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490670.